Why FibroBiologics, Inc.’s (FBLG) Stock Is Down 5.07%
As of Tuesday, April 22, FibroBiologics, Inc.’s FBLG share price has dipped by 5.07%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Commentary & Analysis
Why FibroBiologics, Inc.’s (FBLG) Stock Is Down 25.43%
As of Thursday, February 13, FibroBiologics, Inc.’s FBLG share price has dipped by 25.43%, which has investors questioning if this is right time to buy.Tudor Pop
Why FibroBiologics, Inc.’s (FBLG) Stock Is Up 16.25%
As of Friday, February 07, FibroBiologics, Inc.’s FBLG share price has surged by 16.25%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | FBLG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9.6 | $262.9 | 6% |
|
| Shares Out (Mil) | 6.3 | 54.4 | 16% |
|
| Institutional Ownership | 58.1% | 92.9% | 38% |
|
| Float (Mil) | 6.0 | 41.5 | 14% |
|
| Beta | 1.17 | 0.94 | 69% |
|
| Avg Daily Volume (000s) | 361 | 496 | 54% |
|
| Price Change (52-week) |
(86.7%) | 54.5% | 5% |
|
| Growth | FBLG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (73.0%) | (10.1%) | 4% |
|
| EPS (5yr) | (25.6%) | 15.8% | 10 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.630) | ($3.000) | ($3.250) | |
| Month Ago EPS | ($0.630) | ($3.000) | ($3.250) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.940) | ($4.010) | ($4.490) | |
| Year/Year Chg | (4.0%) | (64.1%) | (52.1%) | |
| Financials | FBLG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($18) | ($43) | 25% |
|
| EPS (TTM) | ($4.766) | ($1.500) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | ($31) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 17% |
|
| Enterprise Value (Q1) (Mil) | $3 | $179 | 4% |
|
| Valuation | FBLG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.89 | 2.56 | 49% |
|
| P/E | na | 18.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | FBLG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.2% | na |
|
| Net Margin | na | (73.0%) | na |
|
| ROA | (166.1%) | (47.9%) | 3% |
|
| ROE | (660.1%) | (55.0%) | 1% |
|
| Liabilities to Assets | 41.5% | 29.4% | 32% |
|
| F-Score | 3 | 2 | 18% |
|
FibroBiologics, Inc. did not pass any screens on 9/15/2026.
